New York, NY (PRWEB) November 26, 2012
This month, The Ontario Genomics Institute, a private not-for-profit life sciences company made an investment in Toronto-based Tissue Regenerative Therapeutics (TRT), a company that aims to use umbilical mesenchymal stem cells (MSCs) to treat a variety of serious medical conditions. This investment will be used by TRT to take the next steps toward initiating human clinical trials. This comes just months after Californias UC Davis Health System received $ 53 million in grants to conduct research studies designed to lead to U.S. Food and Drug Administration approval of human clinical trials using MSCs.
MSCs, which can easily be harvested from umbilical cord tissue and placenta tissue when a baby is born, are in fact currently the subject of over 200 clinical trials. While MSCs are not yet being used for medical therapies, research has indicated that they hold the promise of being able to someday treat debilitating conditions such as heart disease, type 1 diabetes, lung cancer, Parkinsons Disease, and injuries to bones and cartilage.
Americord Registry offers the ability to preserve MSCs. We are committed to helping parents-to-be expand their babys options for future medical treatment, said Americord CEO Martin Smithmyer. Offering the option to preserve MSCs from umbilical cord tissue and placenta tissue is just one of the ways that we are pioneering best-in-class services in the cord blood industry. We are also working closely with scientists to develop a proprietary product that will significant increase the volume of stem cells that can be preserved when a baby is born.
Americord Registry also offers the ability to preserve stem cells from umbilical cord blood. Parents-to-be can preserve stem cells from just umbilical cord blood, from cord blood and cord tissue, or from cord blood, cord tissue and placenta tissue. For a comparison of Americords prices and services with other leading cord blood companies, visit Americords website.
About Americord Registry